2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 95

An Analysis of Malpractice Litigation in Rheumatology
Abstract Number: 464

an Anti-Fima Antibody Attenuates Porphyromonas Gingivalis-Associated Experimental Arthritis
Abstract Number: 2851

An Antigen Microarray to Rule-out Systemic Lupus Erythematosus, the SLE-Key® Rule-out Test, Performs Well As an Aid in Clinical Practice
Abstract Number: 333

An Assessment of Bone Health and Fracture Risk in a Bariatric Surgery Population at an Urban Medical Center
Abstract Number: 598

An Assessment of the Correlation Between Gender and Anticipated Drug Retention to TNF Inhibitors: A Meta-Regression Analysis
Abstract Number: 1411

An Electronic MDHAQ (multidimensional health assessment questionnaire) Beyond an Electronic RAPID (routine assessment of patient index data): 21.3% of Rheumatoid Arthritis Patients Identified As Having Secondary Fibromyalgia Versus 3.5% By Clinicians
Abstract Number: 363

An Examination of Patient Knowledge and Education in Patients with Osteoporosis, Osteopenia and Normal Bone Mineral Density
Abstract Number: 2915

An Increased Circulating Level of Periostin in Patients with Systemic Sclerosis: Associations with Functional Impairment in Various Affected Organs
Abstract Number: 1726

An Integrated Safety Data Analysis Across All Phase II and Phase III Clinical Programs for Ustekinumab in Psoriatic Arthritis, Crohn’s Disease, and Psoriasis
Abstract Number: 941

An International, Multi-Specialty Validation Study of the IgG4-Related Disease Responder Index
Abstract Number: 1577

An Investigation of Translocator Protein As a Tissue and Peripheral Blood Biomarker of Inflammation in Rheumatoid Arthritis
Abstract Number: 2974

An Outcome Survey of 100 Patients with Cerebral Venous Sinus Thrombosis Due to Behcet’s Syndrome Followed up at a Single, Dedicated Center
Abstract Number: 214

Anakinra Compared to Prednisone on the Treatment of Acute CPPD Crystal Arthritis, a Randomized, Controlled, Double-Blind Study
Abstract Number: 215

Anakinra Is Effective and Well Tolerated in Medically Complex Patients Including Transplant Recipients with Gout
Abstract Number: 2186

Analgesic Use and Subsequent Risk of Falls in Participants with or at Risk of Knee Osteoarthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].